Status:
RECRUITING
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
Lead Sponsor:
University of Cologne
Conditions:
Classical Hodgkin Lymphoma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r/r cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy ...
Eligibility Criteria
Inclusion
- Histologically confirmed first relapse of cHL or primary refractory cHL
Exclusion
- Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
Key Trial Info
Start Date :
March 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04838652
Start Date
March 5 2024
End Date
May 1 2028
Last Update
August 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1st Department of Medicine, Cologne University Hospital
Cologne, Germany